Why the C-Suite Decides

Selling to Hospitals

0:00

-18:55

Why the C-Suite Decides

Even When Everyone Doesn't Agree

Lisa T. Miller

May 16, 2026

In episode sixteen of “Selling to Healthcare,” Lisa T. Miller takes on one of the most persistent myths in modern B2B sales — the idea that executives can no longer make meaningful buying decisions without full committee consensus. Drawing on behavioral economics, neuroscience, and real-world case studies, Lisa explains what actually drives the final yes and why the brands that win in healthcare aren’t the loudest or the most feature-rich, but the most trusted.

She unpacks the psychology behind executive decisions — from the powerful role of emotion and personal value, to Kahneman’s Prospect Theory and the risk-aversion that quietly shapes every C-Suite choice. Lisa makes the case that B2B buying is far more emotional than B2C, and that fear of professional risk is often a stronger motivator than the promise of a better outcome.

Lisa then walks through the five-stage architecture of the modern executive buying journey, sharing the data sellers need to understand: most purchase requirements are defined before vendors are ever contacted, peer networks dominate shortlist creation, buying committees have ballooned to 10+ people, and 86% of B2B purchases stall somewhere along the way. She illustrates how the committee builds awareness while the executive still decides — using the Merck/IBM story, where a single CEO-to-CEO conversation overturned a fully-aligned committee recommendation.

This episode offers healthcare sales professionals a clear-eyed playbook for selling to deciders, not just committees — by winning the emotional argument first, reframing the cost of inaction, investing in thought leadership long before the formal evaluation begins, and giving executives the clarity, evidence, and strategic insight to use their authority well.

Highlights of this Episode Include:

The Myth of the Rational Executive: B2B brands drive stronger emotional connections than B2C brands — because the professional stakes of a bad business purchase are enormous, executives won’t commit without trust and emotional buy-in.
Personal Value Beats Business Value: Buyers who see personal value are 71% more likely to buy and 8x more likely to pay a premium — only 14% will pay a premium for business value alone.
The Kahneman Effect: Executives are more motivated to avoid loss than to acquire gain — the most effective sales narratives lead with the cost of inaction, not the benefits of action.
The Invisible Buying Journey: 83% of buyers have mostly or fully defined their purchase requirements before they ever speak with sales — by the time you’re invited in, the shortlist is often already formed.
Peer Networks Build the Shortlist: 73% of B2B executives rank word-of-mouth and peer recommendations as the most influential factor in deciding which vendors to consider — social proof outperforms any vendor demo.
The Committee Informs, the Executive Decides: The Merck/IBM story shows how a unanimous committee recommendation was overturned by a single CEO-to-CEO conversation — authority still exists, it’s just less visible.
Consensus Often Masks Risk-Aversion: Buying committees that have grown to 11, 12, or 15 people aren’t larger because decisions got more complex — they’re larger because willingness to own the tradeoff got smaller.
The Two-Stage Brain: Decisions are made emotionally in the amygdala and justified rationally in the prefrontal cortex — if you haven’t won the emotional argument, no amount of ROI data will close the deal.
Thought Leadership Shapes Decisions Months in Advance: Effective thought leadership engages the 95% of buyers who aren’t actively in-market, reframing assumptions and shaping decisions long before the formal evaluation begins.
Sell to Deciders, Not Just Committees: The work isn’t to assemble a coalition large enough to remove all friction — it’s to give the executive who already has authority the clarity and strategic insight to use it well.